ABOS compared with ACRV: revenue, margins and what each company keeps, and the suppliers and customers both name

ABOSAcumen Pharmaceuticals, Inc.

Mkt capRevenueRevenue

ACRVAcrivon Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ABOSAcumen Pharmaceuticals, Inc.

ACRVAcrivon Therapeutics, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

ABOSAcumen Pharmaceuticals, Inc.

0.24▲+12.33%· post 0.22

Mkt cap$15.2M

ACRVAcrivon Therapeutics, Inc.

1.61▼−3.01%· post 1.61

ClosedNov 2 '26

Mkt cap$12.2M

Compare

ClosedNov 2 '26

ABOSAcumen Pharmaceuticals, Inc.

ACRVAcrivon Therapeutics, Inc.

0.24▲+12.33%post 0.22

Price

1.61▼−3.01%post 1.61

$15.2M

Mkt cap

$12.2M

ABOS0.24▲+12.33%vsACRV1.61▼−3.01%ClosedNov 2 '26

last 4 reports each · paired by recencyMethod ›

ABOS2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▲+14.65%—

Q2 FY26±15.3%▲+1.62%×0.10

ACRV1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+7.56%—

= impliedABOS realized, solidACRV realized, hatchedOne scale, both sides: full bar = 16%× = |realized| ÷ impliedSource: market data